Product Development
We, together with our licensees and collaborators, are currently developing a number of DNA-based vaccines and therapeutics for the
prevention or treatment of infectious diseases, cardiovascular diseases and cancer. Our lead independent development programs focus on
metastatic melanoma, CMV, and pandemic influenza. The table below summarizes our independent programs and corporate and government
collaborations.
14
Product Concept
Intended Use
Development Status
Lead Developer
Independent Programs
Allovectin-7 cancer immunotherapeutic First-line treatment for metastatic melanoma Phase 3 Vical
TransVax™ therapeutic vaccine
for cytomegalovirus
Prevent viral reactivation and disease after
transplant
Phase 2 - enrollment
complete
Vical
Prophylactic vaccine for H5N1
pandemic influenza virus
Protect against infection, disease, and/or viral
shedding
Phase 1 completed
Vical
Prophylactic vaccine for H1N1
pandemic influenza virus
Protect against infection, disease, and/or viral
shedding
Preclinical
Vical
CyMVectin™ prophylactic
vaccine for cytomegalovirus
Prevent infection before and during pregnancy to
preclude fetal transmission
Preclinical
Vical
Therapeutic vaccine for herpes
simplex type 2 virus
Prevent recurring flare-ups to reduce viral
shedding and transmission
Research
Vical
Corporate Collaborations
Collategene™ angiogenic
therapy encoding Hepatocyte
Growth Factor
Induce local growth of blood vessels to restore
blood flow to limbs affected by ischemia
NDA filed in Japan,
Phase 2 completed
in the
United States
AnGes
Angiogenic therapy encoding
Fibroblast Growth Factor 1
Induce local growth of blood vessels to restore
blood flow to limbs affected by ischemia
Phase 3 – enrollment
complete
Sanofi-aventis
Angiogenic therapy encoding
Hepatocyte Growth Factor
Induce local growth of blood vessels to restore
blood flow to heart affected by ischemia
Phase 1 completed in
the United States
AnGes
Therapeutic vaccine encoding
carcinoembryonic antigen and
human epidermal growth
factor receptor 2
Treat breast, colorectal, ovarian or non-small cell
lung cancer
Phase 1
Merck
Therapeutic vaccine encoding
human telomerase reverse
transcriptase
Treat non-small cell lung, breast or prostate
cancer, melanoma, or carcinomas of the upper
GI tract, colon, kidney, or bladder
Phase 1
Merck
Prophylactic and/or therapeutic
hepatitis C vaccine
Prevent and/or treat infection, disease,
and/or viral shedding
Research
Merck
Apex-IHN prophylactic vaccine
for infectious hematopoietic
necrosis virus
Protect farm-raised salmon from infection and
disease when exposed to infected wild salmon
Marketed in Canada
Aqua Health
(Novartis)
Therapeutic cancer vaccine
encoding human tyrosinase
Adjunct treatment to increase survival time of
dogs with oral melanoma
Conditional approval
in the
United States
Merial
Government Collaborations
Prophylactic and/or therapeutic
HIV vaccine
Prevent and/or treat infection, disease,
and/or viral shedding
Phase 2
NIH